Favipiravir-Induced Drug Fever in a Young Adult COVID-19 Patient

Severe acute respiratory syndrome coronavirus 2 has had an indelible effect, with 153,738,171 cases recorded globally as per the World Health Organization’s dashboard. The medical establishment is racing to find repurposed medications that can be successful against this novel coronavirus due to a sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Jadeja, Dhigishaba M, Patel, Nirmit R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189533/
https://www.ncbi.nlm.nih.gov/pubmed/34123627
http://dx.doi.org/10.7759/cureus.14928
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 has had an indelible effect, with 153,738,171 cases recorded globally as per the World Health Organization’s dashboard. The medical establishment is racing to find repurposed medications that can be successful against this novel coronavirus due to a shortage of new drugs to treat the disease. Favipiravir, an antiviral drug originally developed for influenza, is one of the drugs that has recently received a lot of attention, particularly in India. Here, we present a case of favipiravir-induced drug fever in a young adult coronavirus disease 2019 patient.

Ejemplares similares